TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Nanologica AB ( (SE:NICA) ) is now available.
Nanologica AB has secured an additional order worth approximately SEK 2.7 million from a US-based peptide drug manufacturer for its silica-based purification media, NLAB Saga®. This supplementary order follows an initial order placed in June and indicates the customer’s intent to evaluate the product for potential inclusion in their production processes. The order underscores Nanologica’s stable production capabilities and is expected to be delivered in the fourth quarter, potentially enhancing the company’s market positioning and stakeholder value.
The most recent analyst rating on (SE:NICA) stock is a Hold with a SEK1.00 price target. To see the full list of analyst forecasts on Nanologica AB stock, see the SE:NICA Stock Forecast page.
More about Nanologica AB
Nanologica AB is a Swedish life science tools company that specializes in developing, manufacturing, and selling advanced consumables for pharmaceutical manufacturers. The company’s products are designed for the purification of peptide drugs, such as insulin and GLP-1 analogues, aiming to increase productivity and reduce costs for drug manufacturers. Operating in a growing global niche market driven by the rising demand for diabetes and obesity treatments, Nanologica is headquartered in Södertälje and its shares are listed on Nasdaq Stockholm Main Market.
Average Trading Volume: 125,050
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK106M
For detailed information about NICA stock, go to TipRanks’ Stock Analysis page.